Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Granular corneal dystrophy type II (GCD2) is an autosomal dominant stromal dystrophy caused by heterozygous mutations in the transforming growth factor beta-induced gene (TGFBI) leading to progressive opacification and vision impairment. The association between TGFBI and GCD2 meets Definitive clinical validity based on 117 patients (PMID:11095060) from 88 independent families (PMID:11095060), segregation of the recurrent R124H variant in multiple pedigrees, and concordant in vitro amyloidogenesis assays (PMID:12392546).
Autosomal dominant inheritance with full penetrance in homozygotes and variable expressivity in heterozygotes. In one Chinese pedigree, 6 probands were heterozygous for c.371G>A (p.Arg124His) (PMID:19145249) with segregation in 5 additional affected relatives (PMID:19145249). The R124H missense variant is the predominant pathogenic allele; no loss-of-function or splice variants have been reported. Recurrent R124H arises in diverse populations without a clear founder effect, consistent with a mutational hotspot in exon 4 of TGFBI.
Mechanism: toxic gain-of-function by enhanced amyloidogenicity of mutant protein. In vitro, peptides bearing His124 form significantly more β-pleated sheets and amyloid fibrils than wild-type (PMID:12392546). Cellular models of mutant TGFBIp demonstrate deposition of insoluble aggregates in corneal stroma analogs, mirroring the human phenotype.
No studies have convincingly refuted the pathogenic role of R124H in GCD2; reduced penetrance has been observed for heterozygotes but is due to age-dependent expressivity rather than non-pathogenicity (PMID:19145249).
The c.371G>A (p.Arg124His) variant in TGFBI has a definitive gene-disease association with granular corneal dystrophy type II. Genetic testing for R124H enables accurate diagnosis, informs prognosis, and guides patient management.
Gene–Disease AssociationDefinitive117 patients (PMID:11095060) from 88 families (PMID:11095060), segregation in multiple pedigrees, concordant amyloidogenesis assays (PMID:12392546) Genetic EvidenceStrong6 probands (PMID:19145249) with segregation in 5 additional affected relatives (PMID:19145249) Functional EvidenceModerateIn vitro amyloid assays show increased β-sheet and fibril formation for His124 peptides (PMID:12392546) |